ARTICLE | Clinical News

Agios posts AML data after day's slump

December 6, 2016 12:48 AM UTC

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) slipped $7.10 (12%) to $49.87 on Monday after reporting new data from Phase I studies of AG-519 and AG-348, two small molecule activators of pyruvate kinase R to treat pyruvate kinase deficiency. After market hours, Agios reported new data from a Phase I study of AG-120 to treat hematological malignancies including acute myelogenous leukemia (AML).

In a Phase I trial of AG-519 in healthy volunteers, the company said it is investigating an ongoing case of drug-related cholestatic hepatitis. The patient received 300 mg AG-519 daily, one of several regimens ranging from 50 mg-1,250 mg in the dose-escalation trial. Agios had previously reported a case of grade 2 thrombocytopenia from the trial, driving down shares by 15% on June 9 (see BioCentury Extra, June 9)...